Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling

Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer